0SZI Stock Chart & Stats
$11.09
-$0.08(-0.92%)
At close: 4:00 PM EDT
$11.09
-$0.08(-0.92%)
Day’s Range― - ―
52-Week Range$6.32 - $24.50
Previous CloseN/A
Volume5.39K
Average Volume (3M)24.09K
Market Cap
$138.10M
Enterprise Value$68.37
Total Cash (Recent Filing)$117.94M
Total Debt (Recent Filing)$4.26M
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Nov 10, 2026EPS Estimate
-1.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.19
Shares Outstanding19,341,293
10 Day Avg. Volume57,700
30 Day Avg. Volume24,087
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.73
Price to Sales (P/S)0.00
P/FCF Ratio-1.68
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$36.67Price Target Upside230.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-5.43
Revenue Forecast (FY)$1.67M
Bulls Say, Bears Say
Bulls Say
Promising Obesity PipelinePositive Phase 1b results give CRB-913 a credible basis for further development in obesity, including differentiated non-incretin positioning and a potentially more tolerable profile. Advancing efficacy and safety evidence can strengthen the pipeline’s strategic value over the next several quarters.
Late-stage Oncology ProgressFDA clearance to begin a registrational Phase 3 study moves CRB-701 toward a potentially decisive development stage and creates a clearer path to future commercialization. The program’s late-stage status can improve portfolio quality and provide an important catalyst beyond early clinical validation.
Liquidity And Low LeverageReported liquidity extending into 2028 provides Corbus with meaningful time to conduct clinical programs without immediate financing pressure. Combined with low reported leverage, this supports operational flexibility and reduces near-term dependence on debt or equity markets while key trials advance.
Bears Say
No Product RevenueThe absence of recurring product revenue means Corbus cannot fund operations through an established commercial franchise. Its financial capacity therefore depends on available capital and potential business-development proceeds, making clinical execution and eventual approval central to building a durable business model.
Widening Losses And Cash BurnAccelerating cash consumption and materially wider losses increase the resources required to sustain Corbus’s development portfolio. Even with reported liquidity, persistent negative cash flow can shorten financial flexibility over time and raise the importance of disciplined spending, milestones, and future funding.
Equity DeteriorationThe decline in equity reflects the cumulative effect of ongoing losses and shows that balance-sheet support can erode as development spending continues. Although current leverage is low, further deterioration could reduce financial resilience and increase reliance on external capital to fund trials.
Corbus Pharmaceuticals News
0SZI FAQ
What was Corbus Pharmaceuticals’s price range in the past 12 months?
Corbus Pharmaceuticals lowest share price was $6.32 and its highest was $24.50 in the past 12 months.
What is Corbus Pharmaceuticals’s market cap?
Corbus Pharmaceuticals’s market cap is $138.10M.
When is Corbus Pharmaceuticals’s upcoming earnings report date?
Corbus Pharmaceuticals’s upcoming earnings report date is Nov 10, 2026 which is in 43 days.
How were Corbus Pharmaceuticals’s earnings last quarter?
Corbus Pharmaceuticals released its earnings results on Aug 06, 2026. The company reported -$1.81 earnings per share for the quarter, missing the consensus estimate of -$1.259 by -$0.551.
Is Corbus Pharmaceuticals overvalued?
According to Wall Street analysts Corbus Pharmaceuticals’s price is currently Undervalued.
Does Corbus Pharmaceuticals pay dividends?
Corbus Pharmaceuticals does not currently pay dividends.
What is Corbus Pharmaceuticals’s EPS estimate?
Corbus Pharmaceuticals’s EPS estimate is -1.21.
How many shares outstanding does Corbus Pharmaceuticals have?
Corbus Pharmaceuticals has 19,341,293 shares outstanding.
What happened to Corbus Pharmaceuticals’s price movement after its last earnings report?
Corbus Pharmaceuticals reported an EPS of -$1.81 in its last earnings report, missing expectations of -$1.259. Following the earnings report the stock price went up 0.521%.
Which hedge fund is a major shareholder of Corbus Pharmaceuticals?
Currently, no hedge funds are holding shares in GB:0SZI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Corbus Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.67 (230.63% Upside)
$36.67 (230.63% Upside)
Blogger Sentiment
Bullish
GB:0SZI Sentiment 100%
Sector Average 64%
Sector Average 64%
Insider Transactions
Bought Shares
Worth $25.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.18%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.52%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
0SZI Stock 12 Month Forecast
Average Price Target
$36.67
▲(230.63% Upside)